India Pharma Outlook Team | Thursday, 03 February 2022
Covid-19 working group of the National Technical Advisory Group on immunisation (NTAGI) is expected to meet on Friday to review trials data of Covovax and Corbevax for their use in children, people in the know said. At present children between the age group of
15-17 years are eligible to receive only Covaxin shots. The drug regulator had on August 20 given emergency use authorisation (EUA) to a three-dose Covid-19 vaccine from Zydus Cadila, the first in India that can be given to people 12 years and above.
However this jab will be first given to adults and will not be given to children immediately. Both SII and Biological E are conducting Phase III trials of their vaccines on children. These could become the next choices of vaccines for the children going forward. The companies will give presentation before the expert group regarding their data on Friday. "The trials data by both the companies will be presented before the NTAGI committee. They will then approach the drug regulator," people said.
, CDSCO.jpg)
